Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients

Hematological Oncology

Volumn 25, Issue 3, 2007, Pages 121-126

  Aref, Salah ^a   Osman, E ^b   Mansy, S ^b   Omer, N ^b   Azmy, E ^a   Goda, T ^a   El Sherbiny, M ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

AML; MMP 2; Prognosis

Indexed keywords

GELATINASE A;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; BLAST CRISIS; FEMALE; HEMOGLOBINS; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PLATELET COUNT; PROGNOSIS;

EID: 34848842112     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.817     Document Type: Article

References (20)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004; 1: 98-117.
2. Krause JR. Morphology and Classification of Acute Myloid Leukemia, Crisan D (ed.). (Laboratory medicine, clinics of North America), 2000; WB Saunders Company: UK, P1.
3. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999; 5: 1115-1124.
4. Aguayo A, Kantarijan H, Manshouri T, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
5. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metaloproteinase (MMPs) and tissue inhibitors of MMP in acute leukemia: potential role of MMP-9 as a surrogate marker to monitor leukemic status in patient with acute myelogenous leukemia. Br J Hematol 2002; 177: 835-841.
6. Leppa S, Saarto T, Vehmanen L, Blomquist C, Elomaa I. A high serum MMP-2 levels is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004; 10: 1057-1063.
7. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297.
8. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004; 50: 87-100.
9. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002; 69: 205-212.
10. Kuittinen O. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in hematological malignancies. Oulu University press 2003; 16: 67-149.
11. Matsuzaki A, Janowska-Wieczorek A. Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases. J Cancer Res Clin Oncol 1997; 123: 100-106.
12. Sawicki G, Matsuzaki A, Janowska-Wieczorek A. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998; 124: 245-252.
13. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 1999; 105: 402-411.
14. Marquez-Curtis LA, Dobrowsky A, Montano J, et al. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol 2001; 115: 595-604.
15. Janowska-Wieczorek A, Matsuzaki A, Marquez A. The hematopoietic microenvironment: matrix metalloproteinases in the hematopoietic microenvironment. Hematology 2000; 4: 515-527.
16. Aref S, El-Sherbiny M, Mabed M, Menessy A, El-Refaei M. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion. Hematology 2003; 8: 385-391.
17. Kuittinen O, Savolainen ER, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res 2001; 25: 125-131.
18. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-1162.
19. Sivula A, Talvensaari-Mattila A, Lundin J, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005; 89: 215-220.
20. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006; 119: 1403-1411.